These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 29249058

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
    Nakatsukasa K, Koyama H, Ouchi Y, Ono H, Sakaguchi K, Matsuda T, Kato M, Ishikawa T, Yamada K, Yoshimura M, Koizumi K, Sakurai T, Shigematsu H, Takahashi S, Taira S, Suzuki M, Narui K, Niikura N, Hasegawa Y, Miura D, Konishi E, Taguchi T, Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society.
    Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
    Hong AR, Kim JH, Lee KH, Kim TY, Im SA, Kim TY, Moon HG, Han WS, Noh DY, Kim SW, Shin CS.
    Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of chemotherapy followed by aromatase inhibitors on bone health of women with ER-positive early breast cancer in real world clinical settings in Greece: Results of the POCHARBI trial conducted by the Hellenic Society of Breast Surgeons.
    Markopoulos C, Koukouras D, Venizelos V, Karyda I, Xepapadakis G, Misitzis J, Kalogerakos K, Poulakaki F, Natsiopoulos J, Zobolas V, Savidou C, Antonopoulou Z, Tzoracoleftherakis E.
    Breast; 2016 Jun; 27():27-34. PubMed ID: 27212697
    [Abstract] [Full Text] [Related]

  • 7. Vertebral bone marrow fat fraction changes in postmenopausal women with breast cancer receiving combined aromatase inhibitor and bisphosphonate therapy.
    Dieckmeyer M, Ruschke S, Rohrmeier A, Syväri J, Einspieler I, Seifert-Klauss V, Schmidmayr M, Metz S, Kirschke JS, Rummeny EJ, Zimmer C, Karampinos DC, Baum T.
    BMC Musculoskelet Disord; 2019 Nov 06; 20(1):515. PubMed ID: 31694630
    [Abstract] [Full Text] [Related]

  • 8. Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
    Leslie WD, Morin SN, Lix LM, Niraula S, McCloskey EV, Johansson H, Harvey NC, Kanis JA.
    Oncologist; 2019 Nov 06; 24(11):1432-1438. PubMed ID: 31292269
    [Abstract] [Full Text] [Related]

  • 9. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K, Blinder VS, Elkin EB.
    J Clin Oncol; 2012 May 01; 30(13):1468-75. PubMed ID: 22370313
    [Abstract] [Full Text] [Related]

  • 10. AI-related BMD variation in actual practice conditions: A prospective cohort study.
    Rodríguez-Sanz M, Prieto-Alhambra D, Servitja S, Garcia-Giralt N, Garrigos L, Rodriguez-Morera J, Albanell J, Martínez-García M, González I, Diez-Perez A, Tusquets I, Nogués X.
    Endocr Relat Cancer; 2016 Apr 01; 23(4):303-12. PubMed ID: 26911377
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
    Lancet Oncol; 2008 Sep 01; 9(9):840-9. PubMed ID: 18718815
    [Abstract] [Full Text] [Related]

  • 12. Practical guidance for the management of aromatase inhibitor-associated bone loss.
    Hadji P, Body JJ, Aapro MS, Brufsky A, Coleman RE, Guise T, Lipton A, Tubiana-Hulin M.
    Ann Oncol; 2008 Aug 01; 19(8):1407-1416. PubMed ID: 18448451
    [Abstract] [Full Text] [Related]

  • 13. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
    Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE.
    Cancer; 2008 Mar 01; 112(5):1001-10. PubMed ID: 18205185
    [Abstract] [Full Text] [Related]

  • 14. Bisphosphonates may protect against bone loss in postmenopausal women with early breast cancer receiving adjuvant aromatase inhibitor therapy: results from a meta-analysis.
    Su G, Xiang Y, He G, Jiang C, Li C, Yan Z, Zhong Y.
    Arch Med Res; 2014 Oct 01; 45(7):570-9. PubMed ID: 25450582
    [Abstract] [Full Text] [Related]

  • 15. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
    Nakatsukasa K, Koyama H, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, Kato M, Konishi E, Taguchi T.
    J Bone Miner Metab; 2019 Sep 01; 37(5):864-870. PubMed ID: 30868270
    [Abstract] [Full Text] [Related]

  • 16. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
    Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE, ATAC Trialists' group.
    J Bone Miner Res; 2006 Aug 01; 21(8):1215-23. PubMed ID: 16869719
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
    Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S.
    J Clin Oncol; 2008 Oct 20; 26(30):4875-82. PubMed ID: 18725648
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.